Lunlekitug Biosimilar Monoclonal Antibody (IL-1α) for Research

Cat No.: GMP-Bios-INN-1271

Anti-IL1A therapeutic antibody (Pre-made Lunlekitug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Lunlekitug (development code XB20-12) is a monoclonal antibody targeting interleukin-1 alpha (IL-1A). It is developed by XBiotech Inc..

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1271-1mg 1mg 3090
GMP-Bios-INN-1271-10mg 10mg
GMP-Bios-INN-1271-100mg 100mg
GMP-Bios-INN-1271-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Lunlekitug biosimilar, Whole mAb, Anti-IL1A Antibody: Anti-IL1/IL-1A/IL1F1/IL1-ALPHA therapeutic antibody
INN Name Lunlekitug
Target IL1A
Format Whole mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status Active
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2024
Year Recommended na
Companies XBiotech Inc.
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC